Research programme: biosimilars - JHL Biotech

Drug Profile

Research programme: biosimilars - JHL Biotech

Alternative Names: JHL 1101; JHL 1147; JHL 1188; JHL 1227; JHL 1921

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator JHL Biotech
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Cystic fibrosis

Most Recent Events

  • 05 Dec 2016 JHL Biotech and Sanofi collaborate on the development and commercialisation of biological therapeutics in China
  • 14 Feb 2016 The MHRA approves IND application for JHL1101 in Autoimmune disorders
  • 03 Jun 2015 Research programme: biosimilars - JHL Biotech is available for licensing in World as of 18 May 2015. http://www.jhlbiotech.com/index.php
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top